Impact of Obesity on Outcomes of Operable Breast Cancer: A Retrospective Cohort Study.
Body mass index
Obesity
Prognosis
breast cancer
disease-free survival
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Apr 2020
01 Apr 2020
Historique:
received:
06
07
2019
entrez:
26
4
2020
pubmed:
27
4
2020
medline:
2
2
2021
Statut:
epublish
Résumé
Obesity is increasing worldwide. Previous studies of the impact of obesity on breast cancer outcomes have reported conflicting results. We investigated the association of obesity and breast cancer survival in Thai patients. Medical records of operable breast cancer patients diagnosed and treated at Siriraj Hospital between January 2004 and December 2011 were reviewed. Demographic data, tumor characteristics, stage, treatment and adverse event were described. Obesity was defined as body mass index (BMI) ≥ 25 kg/m2 using Asian's cutoff value. Survivals in both obese and non-obese patient groups were analyzed. A total of 400 patients were included, 200 in each group. Obese patients were older and associated with more comorbidity. Obesity was associated with larger tumor size (p = 0.011), greater numbers of lymph node involvement (p = 0.003) and more advanced stage (p = 0.01). Obese patients were more likely to receive less adjuvant chemotherapy and hormonal treatment. There was no statistically significant difference in disease-free survival (DFS) (Hazard ratio [HR] 0.72, 95% confidence interval [CI] 0.46 to 1.13) and overall survival (OS) (HR 0.77, 95% CI 0.43 to 1.39) between obese and non-obese patients. Interestingly, obesity was associated with fewer complications from chemotherapy than non-obese patients (p = 0.047). Obesity had no adverse prognostic impact association on both DFS and OS in Thai patients with operable breast cancer, although obese patients more often presented with larger tumor and higher numbers of lymph node involvement.<br />.
Identifiants
pubmed: 32334455
doi: 10.31557/APJCP.2020.21.4.953
pmc: PMC7445975
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
953-960Références
Cancer Med. 2016 Jun;5(6):1328-40
pubmed: 26923549
Breast Cancer Res. 2015 Sep 18;17:129
pubmed: 26385214
Discov Med. 2015 Sep;20(109):121-8
pubmed: 26463093
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Breast Cancer Res. 2013 Nov 06;15(6):R105
pubmed: 24192331
J Occup Health. 2003 Nov;45(6):335-43
pubmed: 14676412
Clin Oncol (R Coll Radiol). 2016 Sep;28(9):597-603
pubmed: 26936608
Lancet. 2016 Aug 20;388(10046):776-86
pubmed: 27423262
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Annu Rev Med. 2015;66:281-96
pubmed: 25423596
Lancet. 2005 Sep 24-30;366(9491):1108-10
pubmed: 16182899
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Ann Oncol. 2014 Oct;25(10):1901-14
pubmed: 24769692
Int J Cancer. 2002 Mar 10;98(2):279-83
pubmed: 11857420
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Acta Oncol. 2001;40(1):67-71
pubmed: 11321664
Breast Cancer Res Treat. 2011 Sep;129(2):565-74
pubmed: 21499688
Breast Cancer Res Treat. 2012 Nov;136(2):323-30
pubmed: 22918525
Curr Drug Metab. 2006 Jan;7(1):67-81
pubmed: 16454693
Prim Care. 2016 Mar;43(1):121-35, ix
pubmed: 26896205
J Clin Oncol. 2011 Jan 1;29(1):25-31
pubmed: 21115856
Med Oncol. 2014 Apr;31(4):881
pubmed: 24549982
Breast. 2015 Nov;24 Suppl 2:S56-9
pubmed: 26283600
Eur J Cancer. 2014 Feb;50(3):506-16
pubmed: 24315625
Lancet. 2016 Aug 20;388(10046):734-6
pubmed: 27423263
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
J Natl Cancer Inst. 2015 Sep 30;107(12):djv275
pubmed: 26424778
J Clin Oncol. 2012 May 1;30(13):1553-61
pubmed: 22473167
Breast Cancer Res Treat. 2010 Jan;119(1):145-53
pubmed: 19731015